1168 related articles for article (PubMed ID: 18703943)
1. Prevalence of ocular surface disease in glaucoma patients.
Leung EW; Medeiros FA; Weinreb RN
J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
[TBL] [Abstract][Full Text] [Related]
2. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
3. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
[TBL] [Abstract][Full Text] [Related]
4. Ocular surface disease and quality of life in patients with glaucoma.
Skalicky SE; Goldberg I; McCluskey P
Am J Ophthalmol; 2012 Jan; 153(1):1-9.e2. PubMed ID: 21872203
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
6. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
7. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
8. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
[TBL] [Abstract][Full Text] [Related]
9. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
10. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
11. Symptoms and signs of tear film dysfunction in glaucomatous patients.
Valente C; Iester M; Corsi E; Rolando M
J Ocul Pharmacol Ther; 2011 Jun; 27(3):281-5. PubMed ID: 21557633
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival and corneal pneumatic sensitivity is associated with signs and symptoms of ocular dryness.
Situ P; Simpson TL; Fonn D; Jones LW
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):2971-6. PubMed ID: 18390645
[TBL] [Abstract][Full Text] [Related]
13. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
14. Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
[TBL] [Abstract][Full Text] [Related]
15. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
[TBL] [Abstract][Full Text] [Related]
16. The features of dry eye disease in a Japanese elderly population.
Uchino M; Dogru M; Yagi Y; Goto E; Tomita M; Kon T; Saiki M; Matsumoto Y; Uchino Y; Yokoi N; Kinoshita S; Tsubota K
Optom Vis Sci; 2006 Nov; 83(11):797-802. PubMed ID: 17106406
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease.
Hardten DR; Brown MJ; Pham-Vang S
Curr Med Res Opin; 2007 Sep; 23(9):2083-91. PubMed ID: 17822610
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome.
Yoon KC; Im SK; Kim HG; You IC
Cornea; 2011 Sep; 30(9):972-6. PubMed ID: 21705877
[TBL] [Abstract][Full Text] [Related]
19. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ocular surface damage and dry eye status in chronic hepatitis C at different stages of hepatic fibrosis.
Gumus K; Yurci A; Mirza E; Arda H; Oner A; Topaktas D; Karakucuk S
Cornea; 2009 Oct; 28(9):997-1002. PubMed ID: 19724213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
